X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

In survey, PhRMA member companies highlight impact of IPI on R&D

By Katie Verb  |    February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....   Read More

ICYMI: New study reinforces dangers of proposed IPI model

By Nicole Longo  |    January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...   Read More

PhRMA comments to administration on International Pricing Index Model

By Nicole Longo  |    January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...   Read More

10 things you should know about medicine spending and costs

By Holly Campbell  |    January 2, 2019
Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that enhance the...   Read More

ICYMI: WSJ and NYT highlight concerns with Part B International Pricing Index Model

By Nicole Longo  |    December 19, 2018
Medicare Part B is a market-based system that has enabled millions of seniors and patients with disabilities to access needed medicines. Reimbursement for medicines in Part B is based on the ...   Read More

Groups sound the alarm on administration’s new Part B proposal

By Nicole Longo  |    November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...   Read More

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

PhRMA comments in response to request for information on competitive bidding program in Medicare Part B

By Nicole Longo  |    September 25, 2018
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule,...   Read More

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

By Nicole Longo  |    August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...   Read More

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates